Cargando…

Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study

BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/Jun...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahlert, Christian R, Strahm, Carol, Güsewell, Sabine, Cusini, Alexia, Brucher, Angela, Goppel, Stephan, Möller, Elisabeth, Möller, J Carsten, Ortner, Manuela, Ruetti, Markus, Stocker, Reto, Vuichard-Gysin, Danielle, Besold, Ulrike, McGeer, Allison, Risch, Lorenz, Friedl, Andrée, Schlegel, Matthias, Vernazza, Pietro, Kuster, Stefan P, Kohler, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371307/
https://www.ncbi.nlm.nih.gov/pubmed/36905145
http://dx.doi.org/10.1093/cid/ciad143
_version_ 1785078119630110720
author Kahlert, Christian R
Strahm, Carol
Güsewell, Sabine
Cusini, Alexia
Brucher, Angela
Goppel, Stephan
Möller, Elisabeth
Möller, J Carsten
Ortner, Manuela
Ruetti, Markus
Stocker, Reto
Vuichard-Gysin, Danielle
Besold, Ulrike
McGeer, Allison
Risch, Lorenz
Friedl, Andrée
Schlegel, Matthias
Vernazza, Pietro
Kuster, Stefan P
Kohler, Philipp
author_facet Kahlert, Christian R
Strahm, Carol
Güsewell, Sabine
Cusini, Alexia
Brucher, Angela
Goppel, Stephan
Möller, Elisabeth
Möller, J Carsten
Ortner, Manuela
Ruetti, Markus
Stocker, Reto
Vuichard-Gysin, Danielle
Besold, Ulrike
McGeer, Allison
Risch, Lorenz
Friedl, Andrée
Schlegel, Matthias
Vernazza, Pietro
Kuster, Stefan P
Kohler, Philipp
author_sort Kahlert, Christian R
collection PubMed
description BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. RESULTS: Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. CONCLUSIONS: Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population.
format Online
Article
Text
id pubmed-10371307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103713072023-07-27 Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study Kahlert, Christian R Strahm, Carol Güsewell, Sabine Cusini, Alexia Brucher, Angela Goppel, Stephan Möller, Elisabeth Möller, J Carsten Ortner, Manuela Ruetti, Markus Stocker, Reto Vuichard-Gysin, Danielle Besold, Ulrike McGeer, Allison Risch, Lorenz Friedl, Andrée Schlegel, Matthias Vernazza, Pietro Kuster, Stefan P Kohler, Philipp Clin Infect Dis Major Article BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. RESULTS: Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. CONCLUSIONS: Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population. Oxford University Press 2023-03-11 /pmc/articles/PMC10371307/ /pubmed/36905145 http://dx.doi.org/10.1093/cid/ciad143 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Kahlert, Christian R
Strahm, Carol
Güsewell, Sabine
Cusini, Alexia
Brucher, Angela
Goppel, Stephan
Möller, Elisabeth
Möller, J Carsten
Ortner, Manuela
Ruetti, Markus
Stocker, Reto
Vuichard-Gysin, Danielle
Besold, Ulrike
McGeer, Allison
Risch, Lorenz
Friedl, Andrée
Schlegel, Matthias
Vernazza, Pietro
Kuster, Stefan P
Kohler, Philipp
Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title_full Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title_fullStr Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title_full_unstemmed Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title_short Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
title_sort post-acute sequelae after severe acute respiratory syndrome coronavirus 2 infection by viral variant and vaccination status: a multicenter cross-sectional study
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371307/
https://www.ncbi.nlm.nih.gov/pubmed/36905145
http://dx.doi.org/10.1093/cid/ciad143
work_keys_str_mv AT kahlertchristianr postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT strahmcarol postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT gusewellsabine postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT cusinialexia postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT brucherangela postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT goppelstephan postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT mollerelisabeth postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT mollerjcarsten postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT ortnermanuela postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT ruettimarkus postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT stockerreto postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT vuichardgysindanielle postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT besoldulrike postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT mcgeerallison postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT rischlorenz postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT friedlandree postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT schlegelmatthias postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT vernazzapietro postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT kusterstefanp postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT kohlerphilipp postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy
AT postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy